| Piriprost (potassium salt)5-lipoxygenase inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
Piriprost (potassium salt) Dilution Calculator
calculate
Piriprost (potassium salt) Molarity Calculator
calculate
| Cas No. | 88851-62-1 | SDF | Download SDF |
| Synonyms | U-60257B | ||
| Chemical Name | 1,4(R),5(R),6-tetrahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-1-octenyl]-1-phenyl-cyclopenta[b]pyrrole-2-pentanoic acid, monopotassium salt | ||
| Canonical SMILES | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC2=C1C=C(CCCCC([O-])=O)N2C3=CC=CC=C3.[K+] | ||
| Formula | C26H34NO4 • K | M.Wt | 463.7 |
| Solubility | ≤43mg/ml in ethanol;30mg/ml in DMSO;8.6mg/ml in dimethyl formamide | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Piriprost (U 60257) is a leukotriene synthesis inhibitor [1].
Leukotrienes belong to a family of eicosanoid inflammatory mediators produced in leukocytes. Leukotrienes mainly act on a subfamily of G protein-coupled receptors. The production of leukotrienes is implicated in triggerring contractions in the smooth muscles lining the bronchioles and is a major cause of inflammation in asthma and allergic rhinitis [2].
Piriprost inhibited the formation of 5-hydroxyeicosatetraenoic acid (5-HETE), LTB4, and the sulfidopeptide leukotrienes with the IC50 values ranged from 9 to 14 μM for the mouse mast cells and 15-50 μM for the basophil leukemia cells. Piriprost weakly inhibited the solubilized LTC synthase of rat basophil leukemia cells with the IC50 of 1.5 mM [1]. Piriprost increased alkaline phosphatase (ALP) activity in cultured endometrial stromal cells. Piriprost (100 μM) inhibited 5-lipoxygenase activity and decreased 5-hydroxy-eicosatetraenoic acid (a 5-lipoxygenase product) by 53% [3].
In smoke-exposed rabbits, pretreatment with piriprost attenuated the smoke-induced increase in alveolar-capillary barrier permeability and decrease in plasminogen activator activity and causes a swelling of type I alveolar epithelium [4].
References:[1] Bach M K, Brashler J R, White G J, et al. Experiments on the mode of action of piriprost (U-60,257), an inhibitor of leukotriene formation in cloned mouse mast cells and in rat basophil leukemia cells[J]. Biochemical pharmacology, 1987, 36(9): 1461-1466.[2] Smith M J H, Ford‐Hutchinson A W, Bray M A. Leukotriene B: a potential mediator of inflammation[J]. Journal of Pharmacy and Pharmacology, 1980, 32(1): 517-518.[3] Cejic S S, Kennedy T G. Examination of the effects of piriprost (U-60,257 B) on alkaline phosphatase activity of rat endometrial stromal cells in vitro[J]. Prostaglandins, 1991, 42(2): 179-189.[4] itten M L, Grad R, Quan S F, et al. Piriprost pretreatment attenuates the smoke-induced increase in 99mTcDTPA lung clearance[J]. Experimental lung research, 1990, 16(4): 339-353.
